Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Agyrax
2. Antivert
3. Bonamine
4. Bonine
5. Chiclida
6. D Vert
7. D-vert
8. Dihydrochloride, Meclizine
9. Dvert
10. Histametizyn
11. Hydrochloride, Meclizine
12. Meclizine
13. Meclizine Dihydrochloride
14. Meclizine Hydrochloride
15. Meclizine Monohydrochloride
16. Meclozine
17. Monohydrochloride, Meclizine
18. Parachloramine
19. Ru Vert M
20. Ru-vert-m
1. Meclizine Hydrochloride
2. Meclizine Dihydrochloride Monohydrate
3. 31884-77-2
4. Postafen
5. Agyrax
6. Bonamine
7. Hdp7w44cio
8. Meclozine Hydrochloride Monohydrate
9. Ucb-5062
10. 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine;hydrate;dihydrochloride
11. Nsc-757094
12. Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)-, Dihydrochloride, Monohydrate
13. Mfcd00941489
14. Meclizine Hcl Hydrate
15. Nsc-28728
16. Unii-hdp7w44cio
17. Antivert (tn)
18. Chembl3989555
19. Chebi:31805
20. Dtxsid30953792
21. Meclizine Hydrochloride (jan/usp)
22. Meclizine Hydrochloride [usp:jan]
23. Bcp13363
24. Meclizine Hydrochloride [jan]
25. Meclizine Hydrochloride [vandf]
26. Nsc 757094
27. 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine Dihydrochloride Monohydrate
28. Meclizine Hydrochloride [usp-rs]
29. As-13740
30. Meclizine Hydrochloride [orange Book]
31. D01317
32. Meclizine Hydrochloride [usp Monograph]
33. A821043
34. Meclizine Dihydrochloride Monohydrate [mi]
35. (+/-)-meclizine Dihydrochloride Monohydrate
36. Meclozine Hydrochloride Monohydrate [who-dd]
37. Meclizine Dihydrochloride Monohydrate, (+/-)-
38. Q27279880
39. 1-((4-chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazine Dihydrochloride Hydrate
40. 1-((4-chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazinedihydrochloridehydrate
41. 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl) Piperazine Dihydrochloride Monohydrate
42. 1-(p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine Dihydrochloride Monohydrate
43. 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine--hydrogen Chloride--water (1/2/1)
44. 1-[(4-chlorophenyl)-phenyl-methyl]-4-(m-tolylmethyl)piperazine Hydrate Dihydrochloride;meclizine Dihydrochloride Monohydrate
45. 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine Dihydrochloride Hydrate
| Molecular Weight | 481.9 g/mol |
|---|---|
| Molecular Formula | C25H31Cl3N2O |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 480.150197 g/mol |
| Monoisotopic Mass | 480.150197 g/mol |
| Topological Polar Surface Area | 7.5 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 448 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
| 1 of 1 | |
|---|---|
| Drug Name | MECLIZINE HYDROCHLORIDE |
| Active Ingredient | MECLIZINE HYDROCHLORIDE |
| Company | AMNEAL PHARMS (Application Number: A201451); EPIC PHARMA LLC (Application Number: A200294); JUBILANT CADISTA (Application Number: A040659); MYLAN PHARMS INC (Application Number: A202640); PAR PHARM (Application Number: A087127); PAR PHARM (Application Number: A087128); SANDOZ (Application Number: A084092); SANDOZ (Application Number: A084843) |
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Cholinergic Antagonists
Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33504
Submission : 2019-03-15
Status : Active
Type : II
Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm :

GDUFA
DMF Review : Reviewed
Rev. Date : 2015-05-19
Pay. Date : 2015-03-27
DMF Number : 29161
Submission : 2015-03-31
Status : Active
Type : II
Certificate Number : R0-CEP 2019-020 - Rev 00
Issue Date : 2020-04-07
Type : Chemical
Substance Number : 622
Status : Suspended by Holder
NDC Package Code : 54469-0002
Start Marketing Date : 2016-12-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 767
Submission : 1963-12-19
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6370
Submission : 1986-05-22
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3689
Submission : 1980-01-16
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 767
Submission : 1963-12-19
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6370
Submission : 1986-05-22
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20470
Submission : 2007-04-23
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3665
Submission : 1979-12-21
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21987
Submission : 2008-12-05
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2847
Submission : 1977-02-04
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19419
Submission : 2006-04-28
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3689
Submission : 1980-01-16
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5050
Submission : 1983-07-28
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5045
Submission : 1983-11-28
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2017-031 - Rev 01
Status : Valid
Issue Date : 2025-08-08
Type : Chemical
Substance Number : 622

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2011-078 - Rev 03
Status : Valid
Issue Date : 2025-10-20
Type : Chemical
Substance Number : 622

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2015-242 - Rev 00
Status : Valid
Issue Date : 2021-09-10
Type : Chemical
Substance Number : 622

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2019-020 - Rev 00
Status : Suspended by Holder
Issue Date : 2020-04-07
Type : Chemical
Substance Number : 622

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Pharm-Rx has earned an outstanding reputation since its establishment in 1991, serving as a reputable importer and distributor of active ingredients to the pharmaceutical, nutritio...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Our endeavours also lie in the import, and domestic sourcing of raw materials from reliable vendors of the market. We have an excellent infrastructure with world class cGMP facilit...
About the Company : With 33 years of CONSISTENCY, CREDIBILITY & CONTINUITY, D K Pharma has established its presence in the Global Market for Manufacturing Bulk Drugs, Speciality Fine Chemicals and Adv...

About the Company : Osmopharm S.A. is a GMP approved pharmaceutical company located in Switzerland and specialized in development and production of modified release solid oral form drugs under contrac...

About the Company : Established in 1984, R L Fine Chem Pvt. Ltd. is one of the fastest growing API companies, with a leadership position in several APIs such as antihistamines, antidepressants and mus...

About the Company : RR LIFESCIENCES manufactures products purely by organic synthesis to offer its customers a choice of products in their areas. Our facilities are equipped with a range of reactor si...

About the Company : Srikem is a trusted source of Active Pharmaceutical Ingredients (APIs) for top pharmaceutical companies around the world. The company was founded in the year 1994 and our founder M...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Meclizine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Motion Sickness.
Lead Product(s): Meclizine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 23, 2020

Lead Product(s) : Meclizine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Meclizine Plasma Levels in Responders and Non-responders
Details : Meclizine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Motion Sickness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2020

Details:
Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.
Lead Product(s): Scopolamine,Meclizine Hydrochloride
Therapeutic Area: Pharmacology/Toxicology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2017

Lead Product(s) : Scopolamine,Meclizine Hydrochloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Motion Sickness Medications and Vestibular Time Constant
Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2017

Details:
Meclizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vertigo.
Lead Product(s): Meclizine Hydrochloride,Inapplicable
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2014

Lead Product(s) : Meclizine Hydrochloride,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Contr...
Details : Meclizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vertigo.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2014

Details:
Meclizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Smoking Cessation.
Lead Product(s): Meclizine Hydrochloride,Nicotine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Philip Morris USA, Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2011

Lead Product(s) : Meclizine Hydrochloride,Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Philip Morris USA, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Meclizine as a Potential Smoking Cessation Treatment
Details : Meclizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Smoking Cessation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2011

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 303-26-4
End Use API : Meclizine Hydrochloride
About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Navical
Dosage Form : Tablet
Dosage Strength : 25MG
Packaging :
Approval Date : 1992-04-01
Application Number : 59405
Regulatory Info : Cancelled
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Navical
Dosage Form : Syrup
Dosage Strength : 5MG
Packaging :
Approval Date : 1992-04-01
Application Number : 59406
Regulatory Info : Cancelled
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Emetostop
Dosage Form : Tablet
Dosage Strength : 30MG
Packaging :
Approval Date : 2014-05-22
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Meclozine Dihydrochloride Monohydrate
Brand Name : Postafen
Dosage Form : Tablet
Dosage Strength : 25mg
Packaging :
Approval Date : 13/09/1954
Application Number : 19540913000011
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Meclozine Dihydrochloride; Caffeine; Pyridoxine Hydrochloride
Brand Name : Itinerol B6
Dosage Form : Suppository
Dosage Strength :
Packaging :
Approval Date : 06/01/1953
Application Number : 18383
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Meclozine Dihydrochloride; Caffeine; Pyridoxine Hydrochloride
Brand Name : Itinerol B6
Dosage Form : Suppository
Dosage Strength :
Packaging :
Approval Date : 06/01/1953
Application Number : 18383
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Meclozine Dihydrochloride; Caffeine; Pyridoxine Hydrochloride
Brand Name : Itinerol B6
Dosage Form : Capsule
Dosage Strength :
Packaging :
Approval Date : 21/04/1977
Application Number : 40770
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Meclozine Dihydrochloride; Pyridoxine Hydrochloride
Brand Name : Itinerol B6
Dosage Form : Suppository
Dosage Strength :
Packaging :
Approval Date : 24/06/1957
Application Number : 23560
Regulatory Info : Allowed
Registration Country : Switzerland

Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Chiclida
Dosage Form : Lozenge
Dosage Strength : 25MG
Packaging :
Approval Date : 1990-05-01
Application Number : 57907
Regulatory Info : Authorized
Registration Country : Spain

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Chiclida
Dosage Form : Medicated Gum
Dosage Strength : 25MG
Packaging :
Approval Date : 1960-05-01
Application Number : 33924
Regulatory Info : Authorized
Registration Country : Spain

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
92
PharmaCompass offers a list of Meclizine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Meclizine Hydrochloride manufacturer or Meclizine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Meclizine Hydrochloride manufacturer or Meclizine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Meclizine Hydrochloride API Price utilized in the formulation of products. Meclizine Hydrochloride API Price is not always fixed or binding as the Meclizine Hydrochloride Price is obtained through a variety of data sources. The Meclizine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Agyrax manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Agyrax, including repackagers and relabelers. The FDA regulates Agyrax manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Agyrax API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Agyrax manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Agyrax supplier is an individual or a company that provides Agyrax active pharmaceutical ingredient (API) or Agyrax finished formulations upon request. The Agyrax suppliers may include Agyrax API manufacturers, exporters, distributors and traders.
click here to find a list of Agyrax suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Agyrax DMF (Drug Master File) is a document detailing the whole manufacturing process of Agyrax active pharmaceutical ingredient (API) in detail. Different forms of Agyrax DMFs exist exist since differing nations have different regulations, such as Agyrax USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Agyrax DMF submitted to regulatory agencies in the US is known as a USDMF. Agyrax USDMF includes data on Agyrax's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Agyrax USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Agyrax suppliers with USDMF on PharmaCompass.
A Agyrax CEP of the European Pharmacopoeia monograph is often referred to as a Agyrax Certificate of Suitability (COS). The purpose of a Agyrax CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Agyrax EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Agyrax to their clients by showing that a Agyrax CEP has been issued for it. The manufacturer submits a Agyrax CEP (COS) as part of the market authorization procedure, and it takes on the role of a Agyrax CEP holder for the record. Additionally, the data presented in the Agyrax CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Agyrax DMF.
A Agyrax CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Agyrax CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Agyrax suppliers with CEP (COS) on PharmaCompass.
A Agyrax written confirmation (Agyrax WC) is an official document issued by a regulatory agency to a Agyrax manufacturer, verifying that the manufacturing facility of a Agyrax active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Agyrax APIs or Agyrax finished pharmaceutical products to another nation, regulatory agencies frequently require a Agyrax WC (written confirmation) as part of the regulatory process.
click here to find a list of Agyrax suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Agyrax as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Agyrax API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Agyrax as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Agyrax and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Agyrax NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Agyrax suppliers with NDC on PharmaCompass.
Agyrax Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Agyrax GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Agyrax GMP manufacturer or Agyrax GMP API supplier for your needs.
A Agyrax CoA (Certificate of Analysis) is a formal document that attests to Agyrax's compliance with Agyrax specifications and serves as a tool for batch-level quality control.
Agyrax CoA mostly includes findings from lab analyses of a specific batch. For each Agyrax CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Agyrax may be tested according to a variety of international standards, such as European Pharmacopoeia (Agyrax EP), Agyrax JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Agyrax USP).